admin, Author at Ona Therapeutics

Biocytogen Enters into Antibody Agreement with Ona Therapeutics to Develop Antibody-Drug Conjugates Targeting Solid Tumors
Gallery

Biocytogen Enters into Antibody Agreement with Ona Therapeutics to Develop Antibody-Drug Conjugates Targeting Solid Tumors

admin2023-12-14T17:45:46+01:00

Biocytogen Enters into Antibody Agreement with Ona Therapeutics to Develop Antibody-Drug Conjugates Targeting Solid Tumorsadmin2023-12-14T17:45:46+01:00

ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors
Gallery

ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors

admin2023-05-22T10:10:31+02:00

ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directorsadmin2023-05-22T10:10:31+02:00

ONA Therapeutics Strengthens Scientific Leadership Team
Gallery

ONA Therapeutics Strengthens Scientific Leadership Team

admin2021-10-20T22:30:57+02:00

ONA Therapeutics Strengthens Scientific Leadership Teamadmin2021-10-20T22:30:57+02:00

March 2021. ONA Therapeutics appoints Mark Throsby to its Board of Directors
Gallery

March 2021. ONA Therapeutics appoints Mark Throsby to its Board of Directors

admin2021-09-17T10:44:08+02:00

March 2021. ONA Therapeutics appoints Mark Throsby to its Board of Directorsadmin2021-09-17T10:44:08+02:00

December 2020. International Consortium Awarded Eurostars Grant for the Development of First-in-class Treatment of Metastatic Cancer
Gallery

December 2020. International Consortium Awarded Eurostars Grant for the Development of First-in-class Treatment of Metastatic Cancer

admin2021-10-01T12:17:02+02:00

December 2020. International Consortium Awarded Eurostars Grant for the Development of First-in-class Treatment of Metastatic Canceradmin2021-10-01T12:17:02+02:00

December 2020. ONA’s scientific co-founder Salvador Aznar Benitah is awarded with the LILIANE BETTENCOURT prize for life sciences.
Gallery

December 2020. ONA’s scientific co-founder Salvador Aznar Benitah is awarded with the LILIANE BETTENCOURT prize for life sciences.

admin2021-10-01T12:19:13+02:00

December 2020. ONA’s scientific co-founder Salvador Aznar Benitah is awarded with the LILIANE BETTENCOURT prize for life sciences.admin2021-10-01T12:19:13+02:00

September 2020. Ona Therapeutics is named as one of Fierce Biotech’s “Fierce 15” Biotech Companies of 2020
Gallery

September 2020. Ona Therapeutics is named as one of Fierce Biotech’s “Fierce 15” Biotech Companies of 2020

admin2021-10-01T12:21:43+02:00

September 2020. Ona Therapeutics is named as one of Fierce Biotech’s “Fierce 15” Biotech Companies of 2020admin2021-10-01T12:21:43+02:00

June 2020. Ona Therapeutics raises €30M in Series A financing
Gallery

June 2020. Ona Therapeutics raises €30M in Series A financing

admin2021-10-19T10:31:13+02:00

June 2020. Ona Therapeutics raises €30M in Series A financingadmin2021-10-19T10:31:13+02:00

April 2020. Barcelona, Spain. Salvador Aznar Benitah, ONA scientific co-founder speaks about entrepreneurship and the new role for scientists.
Gallery

April 2020. Barcelona, Spain. Salvador Aznar Benitah, ONA scientific co-founder speaks about entrepreneurship and the new role for scientists.

admin2021-10-19T10:37:00+02:00

April 2020. Barcelona, Spain. Salvador Aznar Benitah, ONA scientific co-founder speaks about entrepreneurship and the new role for scientists.admin2021-10-19T10:37:00+02:00

January 2020. Monaco, Principality of Monaco. ONA Therapeutics nominated finalist at Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award
Gallery

January 2020. Monaco, Principality of Monaco. ONA Therapeutics nominated finalist at Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award

admin2021-10-19T10:40:16+02:00

January 2020. Monaco, Principality of Monaco. ONA Therapeutics nominated finalist at Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Awardadmin2021-10-19T10:40:16+02:00

About admin

LEARN MORE ABOUT US

CONTACT INFORMATION

admin

About admin

LEARN MORE ABOUT US

CONTACT INFORMATION

ONA THERAPEUTICS, SL obtains personal data through the contact forms of the web, from those who submit any questions, requests and / or comments.

The purposes for which these data are collected are those of being able to respond to your queries regarding the services we offer. In addition, of the timely response to your queries, we may, if you authorize us to do so, send you information electronically.

We will not proceed with the communication or transfer of your data, in any case, unless a public body requires it in accordance with the Law and those in charge of treatment that provide services related to our information systems.

To protect the privacy of the USERS, it is prohibited to send any information regarding their ideology, religion, beliefs, racial origin, health, and sexual life through our forms.

Likewise, we inform you that, under no circumstances will automated individual decisions or profiling be made.